- inhaled nitric oxide adult cardiac


inhaled nitric oxide adult cardiac -

Inhaled nitric oxide (20 ppm to 30 ppm) was administered for a median duration of 30.2 hours. The group, as a whole, demonstrated a significant decrease in both mean pulmonary artery pressure and right ventric-ular stroke work index. In addition, a significant increase in posttherapeutic cardiac index and PaO2 /FiO2 ratio was observed. Inhaled nitric oxide effectively and selectively lowered right ventricular afterload and right ventricular work in critically ill adult cardiac patients with acute pulmonary hypertension.Cited by: 32.

Aug 24, 2015 · Trummer G, Berchtold-Herz M, Martin J, Beyersdorf F. Successful treatment of pulmonary hypertension with inhaled nitric oxide after pulmonary embolectomy. Ann Thorac Surg 2002; 73:1299. Solina A, Papp D, Ginsberg S, et al. A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. Inhaled nitric oxide (iNO) therapy as a selective pulmonary vasodilator in cardiac surgery has been one of the most significant pharmacological advances in managing pulmonary hemodynamics and life threatening right ventricular dysfunction and failure.Cited by: 12.

May 29, 2009 · Administration of inhaled nitric oxide to adults. The licensed indication of iNO is restricted to persistent pulmonary hypertension in neonates, yet most iNO is administered for unlicensed indications. Pharmaceutical iNO is available at a very high cost, and in light of this and concerns over potential adverse effects of iNO, Cited by: 78. May 29, 2009 · Administration of inhaled nitric oxide to adults. After prolonged use, there is a leftward shift in the dose-response curve such that, without regular titration against a therapeutic goal, there is a risk of excessive iNO administration, associated with toxicity and loss of the therapeutic effect [ 3 ].Cited by: 78.